The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of alternating-week fixed dose rate gemcitabine (FDR gem) plus capecitabine (CAP) in advanced pancreatic cancer (APC).
 
Claire Johns
No Relationships to Disclose
 
Celso L. Diaz
No Relationships to Disclose
 
William Kerridge
No Relationships to Disclose
 
Jimmy Hwang
No Relationships to Disclose
 
Andrew H. Ko
Honoraria - Advance Medical; Med IQ; Medscape; Peerview
Consulting or Advisory Role - ARMO Biosciences; EMD Serono; Genentech/Roche; Halozyme; Incyte; Merrimack; New B Innovation; Seagen
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Acerta Pharma (Inst); Aduro Biotech (Inst); Apexigen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Halozyme (Inst); Merck (Inst); Merrimack (Inst); PRISM BioLab (Inst)
 
Margaret A. Tempero
Consulting or Advisory Role - AstraZeneca; Asuragen; Bayer; Celgene (Inst); EMD Serono; Halozyme (Inst); Lilly; Myriad Genetics; Nucana; Pfizer; Pfizer / EMD Sorono; Portola Pharmaceuticals; Roche/Genentech; Targovax
Research Funding - Celgene (Inst); Halozyme (Inst)
Travel, Accommodations, Expenses - Celgene; EMD Serono; Halozyme; Lilly; Myriad Genetics; Pfizer; Targovax